TG Therapeutics, Inc.

Is TG Therapeutics, Inc. technically bullish or bearish?

As of October 24, 2025, TG Therapeutics, Inc. shows a mildly bearish trend overall, with mixed signals from various indicators, including a mildly bullish weekly MACD and a bearish weekly Bollinger Bands.

As of 24 October 2025, the technical trend for TG Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish. The daily moving averages also reflect a mildly bearish outlook. Bollinger Bands show a bearish signal on the weekly chart but are mildly bullish on the monthly. The KST and OBV are both mildly bullish on the weekly but mildly bearish on the monthly, and Dow Theory supports a mildly bearish view on the weekly while being mildly bullish on the monthly. Overall, the indicators suggest a mildly bearish stance, with no multi-period return data available for comparison to the S&P 500.

Is TG Therapeutics, Inc. overvalued or undervalued?

As of June 30, 2025, TG Therapeutics, Inc. is considered very expensive with a high P/E ratio of 158 and other valuation metrics significantly exceeding its peers, despite impressive 3-year returns of 380.27%.

As of 30 June 2025, the valuation grade for TG Therapeutics, Inc. moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, as evidenced by its high P/E ratio of 158, a Price to Book Value of 26.81, and an EV to EBITDA of 105.38, all of which are substantially higher than its peers. For instance, Catalyst Pharmaceuticals, Inc. has a P/E of 12.14 and an EV to EBITDA of 6.42, highlighting the stark contrast in valuation metrics.<BR><BR>In terms of performance, TG Therapeutics has shown impressive returns, with a 3-year return of 380.27%, significantly outperforming the S&P 500's 70.41% over the same period. However, despite these strong returns, the company's current valuation metrics suggest that it is priced excessively high relative to its earnings and industry peers.

How big is TG Therapeutics, Inc.?

As of Jun 18, TG Therapeutics, Inc. has a market capitalization of $5.56 billion, with recent net sales of $386.40 million and a net profit of $39.15 million. The company reported shareholder's funds of $222.36 million and total assets of $577.69 million as of Dec 24.

Market Cap: As of Jun 18, TG Therapeutics, Inc. has a market capitalization of 5,557.87 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, TG Therapeutics, Inc. reported net sales of 386.40 million and a net profit of 39.15 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 222.36 million and total assets of 577.69 million.

What does TG Therapeutics, Inc. do?

TG Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for B-cell malignancies and autoimmune diseases. As of March 2025, it reported net sales of $121 million and a market cap of approximately $5.56 billion.

Overview: <BR>TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of treatments for B-cell malignancies and autoimmune diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 121 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 5 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 5,557.87 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 158.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.13 <BR>Return on Equity: 16.92% <BR>Price to Book: 23.42<BR><BR>Contact Details: <BR>Address: 2 Gansevoort St Fl 9, NEW YORK NY: 10014-1667 <BR>Tel: 1 212 5544484 <BR>Fax: 1 302 6555049 <BR>Website: http://www.tgtherapeutics.com/

Should I buy, sell or hold TG Therapeutics, Inc.?

Who are in the management team of TG Therapeutics, Inc.?

As of March 2022, TG Therapeutics, Inc.'s management team includes Mr. Michael Weiss as Executive Chairman, President, and CEO, along with independent directors Mr. Laurence Charney, Dr. Yann Echelard, Mr. Kenneth Hoberman, Mr. Daniel Hume, and Dr. William Kennedy.

As of March 2022, the management team of TG Therapeutics, Inc. includes Mr. Michael Weiss, who serves as the Executive Chairman of the Board, President, and Chief Executive Officer. Additionally, the Board of Directors features several independent directors: Mr. Laurence Charney, Dr. Yann Echelard, Mr. Kenneth Hoberman, Mr. Daniel Hume, and Dr. William Kennedy.